Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Six Ways For PD-1 Lung Cancer Programs To Differentiate

Executive Summary

The PD-1 and PD-L1 inhibitors have delivered stellar data in a number of tumor types and hold mega-blockbuster promise – but with so many in the class, sponsors are looking to stand out. Pull-out table provides side-by-side comparison of leading programs.

You may also be interested in...



Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan

All eyes are on Shire in its first quarter of reporting separate figures for its neuroscience division as Takeda ramps up the takeover pressure, while BMS, AbbVie, Sanofi, and Allergan primes pipeline for revenue growth.

PD-1 Data Promise More Shake-ups In Melanoma Standard of Care

Studies presented at AACR highlight pros and cons of two new potential, competing frontline regimens in melanoma – Keytruda alone instead of Yervoy, or Yervoy in combination with Opdivo.

Lung-MAP Patient Screening Should Translate To Cost-Savings

Sponsors say the large number of biomarkers that will be searched for in candidates for the lung cancer trial should allow researchers to find patients much faster, and will offer cost-savings over traditional drug development.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel